Fulcrum Therapeutics’ (FULC) Sector Perform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their sector perform rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research note published on Thursday morning,Benzinga reports. Royal Bank of Canada currently has a $4.00 target price on the stock.

Several other equities analysts have also recently commented on the stock. Leerink Partners reissued a “market perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $22.00 to $3.00 in a research note on Thursday, September 12th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and cut their target price for the stock from $10.00 to $2.00 in a research report on Thursday, September 12th. Cantor Fitzgerald cut shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Finally, HC Wainwright reissued a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Stock Down 9.0 %

NASDAQ:FULC traded down $0.30 during trading hours on Thursday, reaching $3.02. 992,474 shares of the stock were exchanged, compared to its average volume of 988,958. The business has a 50-day moving average of $3.86 and a two-hundred day moving average of $6.51. Fulcrum Therapeutics has a twelve month low of $2.87 and a twelve month high of $13.70. The company has a market capitalization of $188.45 million, a price-to-earnings ratio of -9.84 and a beta of 2.24.

Institutional Trading of Fulcrum Therapeutics

Several large investors have recently modified their holdings of the business. Jane Street Group LLC raised its position in shares of Fulcrum Therapeutics by 54.3% during the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock worth $5,051,000 after purchasing an additional 188,212 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Fulcrum Therapeutics in the second quarter worth $3,084,000. Vanguard Group Inc. lifted its position in shares of Fulcrum Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock valued at $23,965,000 after acquiring an additional 18,681 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Fulcrum Therapeutics during the first quarter valued at $308,000. Finally, Dimensional Fund Advisors LP increased its position in Fulcrum Therapeutics by 13.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company’s stock worth $9,182,000 after purchasing an additional 176,114 shares in the last quarter. 89.83% of the stock is currently owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.